These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17624988)

  • 1. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
    Jaishuen A; Berrios-Rivera JP; Sirisabya N; Zheng HG; Li Y; Kavanagh JJ
    Int J Gynecol Cancer; 2008; 18(2):379-83. PubMed ID: 17624988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
    J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
    Jurado JM; Sánchez A; Pajares B; Pérez E; Alonso L; Alba E
    Clin Transl Oncol; 2008 Sep; 10(9):583-6. PubMed ID: 18796376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
    Penson RT; Dizon DS; Cannistra SA; Roche MR; Krasner CN; Berlin ST; Horowitz NS; Disilvestro PA; Matulonis UA; Lee H; King MA; Campos SM
    J Clin Oncol; 2010 Jan; 28(1):154-9. PubMed ID: 19917843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.
    Bidus MA; Webb JC; Seidman JD; Rose GS; Boice CR; Elkas JC
    Gynecol Oncol; 2006 Jul; 102(1):5-7. PubMed ID: 16697451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.
    Wright JD; Secord AA; Numnum TM; Rocconi RP; Powell MA; Berchuck A; Alvarez RD; Gibb RK; Trinkaus K; Rader JS; Mutch DG
    Int J Gynecol Cancer; 2008; 18(3):400-6. PubMed ID: 17645510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
    Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
    J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
    Hurt JD; Richardson DL; Seamon LG; Fowler JF; Copeland LJ; Cohn DE; Eisenhauer E; Salani R; O'Malley DM
    Gynecol Oncol; 2009 Dec; 115(3):396-400. PubMed ID: 19804901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
    Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
    Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
    Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
    Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer.
    Méndez LE; Mueller A; Salom E; González-Quintero VH
    Obstet Gynecol; 2003 Nov; 102(5 Pt 2):1200-2. PubMed ID: 14607056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
    Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
    Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
    Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
    Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
    Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
    Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.